Načítá se...
HER-2 gene amplification can be acquired as breast cancer progresses
Amplification and overexpression of the HER-2 oncogene in breast cancer is felt to be stable over the course of disease and concordant between primary tumor and metastases. Therefore, patients with HER-2-negative primary tumors rarely will receive anti-Her-2 antibody (trastuzumab, Herceptin) therapy...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
National Academy of Sciences
2004
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC438987/ https://ncbi.nlm.nih.gov/pubmed/15194824 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0402993101 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|